Newron Pharmaceuticals SpA Share Price CBOE EUROPE EQUITIES
Equities
0QOI
IT0004147952
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
Sales 2024 * | 35.98M 38.62M 35.12M 3.08B | Sales 2025 * | 25.95M 27.86M 25.33M 2.22B | Capitalization | 159M 170M 155M 13.57B |
---|---|---|---|---|---|
Net income 2024 * | 7M 7.52M 6.83M 599M | Net income 2025 * | 4M 4.29M 3.9M 342M | EV / Sales 2024 * | 5.22 x |
Net Debt 2024 * | 29.11M 31.25M 28.41M 2.49B | Net Debt 2025 * | 2M 2.15M 1.95M 171M | EV / Sales 2025 * | 6.19 x |
P/E ratio 2024 * |
10.9
x | P/E ratio 2025 * |
36.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Newron Pharmaceuticals SpA
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 14/05/12 |
Luca Benatti
FOU | Founder | 63 | 31/12/97 |
Roberto Galli
DFI | Director of Finance/CFO | - | 31/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 31/12/07 | |
Luca Benatti
FOU | Founder | 63 | 31/12/97 |
Ulrich Köstlin
CHM | Chairman | 71 | 31/12/12 |
1st Jan change | Capi. | |
---|---|---|
-3.47% | 86.16B | |
+2.76% | 40.17B | |
-17.49% | 31.47B | |
+54.44% | 25.24B | |
-13.13% | 15.82B | |
-9.12% | 11.96B | |
-15.45% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |
- Stock Market
- Equities
- NWRN Stock
- 0QOI Stock